Page last updated: 2024-11-12
drymaritin
Description
drymaritin: anti-HIV alkaloid from Drymaria diandra; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
drymaritin : An indole alkaloid that is canthin-6-one substituted by a methoxy group at position 4. Isolated from the whole plants of Drymaria diandra, it exhibits anti-HIV activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Drymaria | genus | [no description available] | Caryophyllaceae | A plant family of the order Caryophyllales, subclass Caryophyllidae, class Magnoliopsida. The species are diverse in appearance and habitat; most have swollen leaf and stem joints.[MeSH] |
Cross-References
Synonyms (7)
| Synonym |
|---|
| drymaritin |
| 4-methoxycanthin-6-one |
| CHEBI:65813 |
| 4-methoxy-6h-indolo[3,2,1-de][1,5]naphthyridin-6-one |
| CHEMBL3609493 |
| 4-methoxy-1,6-diazatetracyclo[7.6.1.05,16.010,15]hexadeca-3,5(16),6,8,10,12,14-heptaen-2-one |
| Q27134304 |
Roles (2)
| Role | Description |
|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| anti-HIV agent | An antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (4)
| Class | Description |
|---|
| indole alkaloid | An alkaloid containing an indole skeleton. |
| enol ether | Ethers ROR' where R has a double bond adjacent to the oxygen of the ether linkage. |
| enone | An alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position. |
| organic heterotetracyclic compound | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1243352 | Antiinflammatory activity in FMLP/CB-induced human neutrophils assessed as inhibition of superoxide anion generation relative to control | 2015 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
| Total synthesis of cordatanine, structural reassignment of drymaritin, and anti-inflammatory activity of synthetic precursors. |
| AID1243354 | Antiinflammatory activity in FMLP/CB-induced human neutrophils assessed as inhibition of elastase release relative to control | 2015 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
| Total synthesis of cordatanine, structural reassignment of drymaritin, and anti-inflammatory activity of synthetic precursors. |
| AID1243351 | Antiinflammatory activity in FMLP/CB-induced human neutrophils assessed as inhibition of superoxide anion generation | 2015 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
| Total synthesis of cordatanine, structural reassignment of drymaritin, and anti-inflammatory activity of synthetic precursors. |
| AID1243353 | Antiinflammatory activity in FMLP/CB-induced human neutrophils assessed as inhibition of elastase release | 2015 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
| Total synthesis of cordatanine, structural reassignment of drymaritin, and anti-inflammatory activity of synthetic precursors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.87
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.87 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.66 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |